ES2441427B1 - Uso de glicolípidos sulfatados como promotores del crecimiento neurítico, la mielinización e inhibidores de la proliferación de astroglia y microglia - Google Patents

Uso de glicolípidos sulfatados como promotores del crecimiento neurítico, la mielinización e inhibidores de la proliferación de astroglia y microglia Download PDF

Info

Publication number
ES2441427B1
ES2441427B1 ES201231045A ES201231045A ES2441427B1 ES 2441427 B1 ES2441427 B1 ES 2441427B1 ES 201231045 A ES201231045 A ES 201231045A ES 201231045 A ES201231045 A ES 201231045A ES 2441427 B1 ES2441427 B1 ES 2441427B1
Authority
ES
Spain
Prior art keywords
sup
group
sub
astroglia
myelination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201231045A
Other languages
English (en)
Other versions
ES2441427A1 (es
Inventor
Manuel Nieto Sampedro
Alfonso FERNÁNDEZ MAYORALAS
Ernesto DONCEL PÉREZ
Isabel García Álvarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (fuhnpaiin)
FUNDACION DEL HOSPITAL NAC DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION FUHNPAIIN
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (fuhnpaiin)
FUNDACION DEL HOSPITAL NAC DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION FUHNPAIIN
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (fuhnpaiin), FUNDACION DEL HOSPITAL NAC DE PARAPLEJICOS PARA LA INVESTIGACION Y LA INTEGRACION FUHNPAIIN, Consejo Superior de Investigaciones Cientificas CSIC filed Critical Fundacion Del Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion (fuhnpaiin)
Priority to ES201231045A priority Critical patent/ES2441427B1/es
Priority to JP2015519258A priority patent/JP2015527985A/ja
Priority to EP13814001.7A priority patent/EP2871183A1/en
Priority to US14/412,649 priority patent/US20150307539A1/en
Priority to PCT/ES2013/070456 priority patent/WO2014006250A1/es
Publication of ES2441427A1 publication Critical patent/ES2441427A1/es
Application granted granted Critical
Publication of ES2441427B1 publication Critical patent/ES2441427B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C07H15/10—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical containing unsaturated carbon-to-carbon bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N21/643—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" non-biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/088—Assessment or manipulation of a chemical or biochemical reaction, e.g. verification whether a chemical reaction occurred or whether a ligand binds to a receptor in drug screening or assessing reaction kinetics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de glicolípidos sulfatados como promotores del crecimiento neurítico, la mielinización e inhibidores de la proliferación de astroglia y microglia.#Uso de un compuesto de fórmula I, donde R{sup,1} es un resto alquenilo C{sub,5}-C{sub,25} que contiene uno o más enlaces carbono-carbono dobles, R{sup,2} se selecciona independientemente del grupo que consiste en metilo y metilo fluorado, al menos uno de R{sup,3} y R{sup,4} es un grupo SO{sub,3}M, donde M se selecciona del grupo que consiste en hidrógeno, metal alcalino, amonio y amina cuaternaria, siendo el otro hidrógeno o acilo; para fabricar un medicamento para tratar patologías del sistema nervioso central seleccionadas del grupo que consiste en lesión por trauma del SNC, enfermedad desmielinizante, enfermedad neuro-inflamatoria y trastorno mental causado por bajo nivel de BDNF. Así como, algunos de estos compuestos de fórmula I, sus procedimientos de obtención y composiciones que los comprenden.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
    imagen5
ES201231045A 2012-07-04 2012-07-04 Uso de glicolípidos sulfatados como promotores del crecimiento neurítico, la mielinización e inhibidores de la proliferación de astroglia y microglia Expired - Fee Related ES2441427B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201231045A ES2441427B1 (es) 2012-07-04 2012-07-04 Uso de glicolípidos sulfatados como promotores del crecimiento neurítico, la mielinización e inhibidores de la proliferación de astroglia y microglia
JP2015519258A JP2015527985A (ja) 2012-07-04 2013-07-02 神経突起伸長、髄鞘形成の促進剤、並びに星状膠細胞及び小膠細胞増殖の阻害剤としての硫酸化糖脂質の使用
EP13814001.7A EP2871183A1 (en) 2012-07-04 2013-07-02 Use of sulphated glycolipids as promoters of neuritic growth and myelination and inhibitors of the proliferation of astroglia and microglia
US14/412,649 US20150307539A1 (en) 2012-07-04 2013-07-02 Use of sulphated glycolipids as promoters of neuritic growth, myelination and inhibiting the proliferation of astroglia and microglia
PCT/ES2013/070456 WO2014006250A1 (es) 2012-07-04 2013-07-02 Uso de glicolípidos sulfatados como promotores del crecimiento neurítico, la mielinización e inhibidores de la proliferación de astroglia y microglia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201231045A ES2441427B1 (es) 2012-07-04 2012-07-04 Uso de glicolípidos sulfatados como promotores del crecimiento neurítico, la mielinización e inhibidores de la proliferación de astroglia y microglia

Publications (2)

Publication Number Publication Date
ES2441427A1 ES2441427A1 (es) 2014-02-04
ES2441427B1 true ES2441427B1 (es) 2015-01-26

Family

ID=49881401

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201231045A Expired - Fee Related ES2441427B1 (es) 2012-07-04 2012-07-04 Uso de glicolípidos sulfatados como promotores del crecimiento neurítico, la mielinización e inhibidores de la proliferación de astroglia y microglia

Country Status (5)

Country Link
US (1) US20150307539A1 (es)
EP (1) EP2871183A1 (es)
JP (1) JP2015527985A (es)
ES (1) ES2441427B1 (es)
WO (1) WO2014006250A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4549185B2 (ja) * 2002-07-10 2010-09-22 生化学工業株式会社 硫酸基転移酵素阻害剤

Also Published As

Publication number Publication date
EP2871183A1 (en) 2015-05-13
WO2014006250A1 (es) 2014-01-09
ES2441427A1 (es) 2014-02-04
JP2015527985A (ja) 2015-09-24
US20150307539A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
CO2018009124A2 (es) Análogos de cannabidiol biológicamente activos
CO2018013635A2 (es) Nuevos compuestos como inhibidores de autotaxina y composiciones farmacéuticas que comprenden a los mismos
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
CO2017001884A2 (es) Polimorfos de selinexor
CU20130116A7 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
AR071480A1 (es) Compuesto de 1- ciano -3- pirrolidinil -bencenosulfonamida composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar la enfermedad pulmonar obstructiva cronica (copd )
CU20160160A7 (es) Compuestos derivados de metoxibencil-pirrolopirimidin-amina como agonistas del receptor tipo toll 7 (tlr7)
ECSP13012892A (es) IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
CL2009000734A1 (es) Compuestos derivados de 4-aminociclohexano sustituido; composicion farmaceutica que comprende a dichos compuestos; y su uso como moduladores del receptor de opioides u y el receptor orl-1 en el tratamiento de la ansiedad, estres, depresion, epilepsia y alzheimer.
AR079226A1 (es) Espiroindolinona- pirrolidinas, procesos de preparacion y uso de los mismos para el tratamiento y profilaxis del cancer
UY35572A (es) Nuevos agonistas del receptor de somatostatina subtipo 4 (sstr4)
AR105522A1 (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
BR112016013874A2 (pt) Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica
AR100715A1 (es) Derivados de alquilo de compuestos 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
AR100713A1 (es) Derivados de amida de compuestos de 1-oxa-4,9-diazaespiro undeceno que tienen actividad multimodal contra el dolor
AR101964A1 (es) Compuestos de imidazopiridazina como moduladores de pi3k
CL2022003047A1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
RU2020108580A (ru) Лекарственное соединение и способы его очистки
RU2016131363A (ru) ПРОИЗВОДНЫЕ АРИЛСУЛЬТАМА В КАЧЕСТВЕ МОДУЛЯТОРОВ ОРФАННОГО РЕЦЕПТОРА γ, СВЯЗАННОГО С РЕТИНОЕВОЙ КИСЛОТОЙ
CL2022003041A1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
MX2017001459A (es) Sintesis de fosforamidatos.
AR074325A1 (es) Compuesto de 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazole, composicion y medicamento que lo comprende y uso y metodo de sintesis del compuesto

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2441427

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150126

FD2A Announcement of lapse in spain

Effective date: 20210915